Kornimate/medical-research-clean huggingface dataset:
effect of osteoanabolic exercises on gait, balance & fear of fall among osteoporotic females

Conditions: Osteoporosis

Summary: with the increase in life expectancy women spend more than one-third of their life time in post-menopausal state leading to osteoporosis in later stages. therefore a decrease in temporal-spatial parameters of gait, high risk of fracture, imbalance in functional parameters, fear of fall and compromised health-related quality of life is observed among osteoporotic females. several physical activities and balance training programs have been implemented globally but nationally no program has yet been designed catering gait balance and fear of fall altogether as a combined program. therefore, the aim of this study was to determine the effectiveness of osteoanabolic exercises on temporal-spatial gait parameters, gait stability ratio (gsr) and bone mineral density (bmd) among the osteoporotic females. moreover, the effectiveness of these exercises was evaluated on dynamic balance using timed up and go test (tug). furthermore, the impact on fear of fall was identified using fall efficacy scaleinternational (fes-i).

a 3-arm randomized controlled trial was conducted at the department of rehabilitation sciences, ziauddin hospital using the envelope method. the participants were screened on the physical activity readiness and you questionnaire (parq \&you). ninety-three osteoporotic females were randomly allocated into three groups; where; participant in group a' received aerobic training protocol, a participant in group b' resistance training and participant in group c' osteoanabolic training. a frequency intensity time type (fitt) protocol according to the american college of sports medicine for aerobic and resistance training was incorporated whereas for osteoanabolic group combination training protocol was used. twelve weeks of training was conducted where pre and post readings were calculated using activpal, tug, fes-i and peripheral dxa scan.

Eligibility criteria:
inclusion criteria: * postmenopausal osteoporotic females aged in between 50-75 years * not participating in any exercise program for the past 3 months * independently ambulatory were included in the study exclusion criteria: • red flags that limit the recruitment of participants in an exercise program, for example, vertebral fracture, an unstable heart condition, malignancy

Keywords: osteoporosis bone mineral density postmenopausal
search for fragility indicators among people aged 50+ with chronic hiv infection

Conditions: Frail in HIV Population

Summary: the frailty and frail elderly was defined in 2001 by fried as a physiological state of heightened vulnerability to external shocks. 5 criteria for classifying the elderly in 3 categories: frail, pre-frail and not frail. the prevalence of frailty in the general population was estimated to be 7%, 10% and 20% for over 65 years and 45% for over 85 years. this concept is explored in some chronic diseases, in order to prevent the loss of autonomy and tailor the treatment. in the carrier population of hiv, a north american retrospective study showed the frailty syndrome manifested as early as 10 years before, than in the general population. furthermore various studies show in this specific population, increased incidence of diseases linked to age, suggesting an accelerated and premature aging. objectives: the objective of this study is to determine the prevalence of frailty defined fried syndrome in a population of subjects aged 50 and over holders of chronic hiv infection.


Eligibility criteria:
inclusion criteria: * patient with hiv and followed in the southeastern france area exclusion criteria: * in patient hiv infected patient * hiv patient disabled (spastic) * hiv infected for less than a year
burning mouth syndrome - new diagnostic criteria and treatment

Conditions: Burning Mouth Syndrome

Summary: the first part of this study is to optimize diagnostic criteria for bms, i.e. not a clinical trial, and will not be covered in this application. the second part will compare topical treatment with clonazepam, capsaicin and placebo in a n-of-1 study design regarding effects of pain, pain-related disability, somatosensory changes in the trigeminal nerve and patient experience in patients with primary bms or other oral mucosal pain. the patients will be treated for two weeks with each drug, with a one-week wash-out period in between. after the last washed-out period, the patients will be able to chose the treatment that they prefer the most and continue with that treatment during 6 months.

the clinical trial in the present study will investigate treatment effects on pain, pain-related disability, jaw function and patients' experiences by topical treatment with clonazepam or capsaicin in comparison with placebo in patients with bms or other oral mucosal pain. twenty patients with primary bms and 20 patients with other oral mucosal pain will be included. the study will comprise a n-of-1-design where each participant will be it's own control. the study will compare topical treatment with clonazepam, capsaicin and placebo regarding effects of pain, pain-related disability, somatosensory changes in the trigeminal nerve and patient experience. primary outcome will be pain intensity and patient experience. the patients will be treated for two weeks with each drug, with a one-week wash-out period in between. after the last washed-out period, the patients will be able to chose the treatment that they prefer the most and continue with that treatment during 6 months. after this 6 months, pain, pain-related disability, somatosensory changes in the trigeminal nerve and patient experience will be assessed again.

Eligibility criteria:
inclusion criteria: * diagnosis of primary bms according to international classification of orofacial pain (icop) or diagnosis of other oral mucosal pains according to icop exclusion criteria: * fibromyalgia * ibs * reflux * recent (\<3 months) intraoral surgical procedure * ongoing medication with clonazepam or capsaicin

Keywords: bms chronic pain pain-related disability somatosensory changes clonazepam capsaicin oral mucosa
determining the immediate effects of counterforce bracing versus kinesiotaping in patients with tennis elbow

Conditions: Tennis Elbow

Summary: the purpose of this study was to compare the immediate efficacy of counterforce brace versus kinesiotaping on patients with lateral epicondylosis/tennis elbow with respect to a repetitive physical task. the investigators hypothesized that there would be difference in the outcomes with respect to interventions and activity. patient came for one hour long single occasion testing session and were not followed up after the testing was complete.

this was a cross over randomized control trial. thirty patients with clinical diagnosis of lateral epicondylosis/tennis elbow were recruited from a local community and were tested on single occasion (one time testing session) before and after a five minute upper extremity repetitive task first with control and then brace and kinesiotape assigned in cross-over design. the testing session was one hour long and there was no follow up of patients following the testing. the patients were recruited between jan-june 2013.

Eligibility criteria:
inclusion criteria: 1. age (18-70 years) 2. ability to provide written informed consent to participate 3. were at least three weeks from onset of symptoms 4. complaints of discomfort or pain at the lateral elbow region for a minimum of three weeks and tenderness with palpation of the lateral epicondyle 5. provocation of lateral elbow pain with one of the following test - resisted middle finger extension, resisted wrist extension or passive stretch of wrist extensors exclusion criteria: 1. history of surgery on affected elbow 2. history of cortisone injections on the affected elbow in the past 4 weeks 3. any physical or mental limitations that precluded performance of the study testing 4. allergy to adhesive tapes

Keywords: tennis elbow, treatment, lateral epicondylitis, immediate effects
effect of vitamin e on skin aerobic bacteria in palmar arsenical keratosis

Conditions: Chronic Arsenic Poisoning

Summary: this study will be conducted to observe any change in aerobic bacterial pattern on the skin of arsenicosis patients before and after administration of vitamin e (200 iu) capsules.

arsenicosis has emerged as one of the main and hazardous public health problem in bangladesh. melanosis and keratosis are the most common manifestations of arsenicosis. the exact mechanism of development of keratosis is not clear. with chronic ingestion of arsenic contaminated water the excretion of arsenic through skin increases and also the oxidative stress, which in turn cause cellular damage. these changes may influence the growth of normal bacteria and consistency of skin, which may be responsible for keratosis. in different study results shown that, vitamin e, a potential antioxidant that halts lipid peroxidation and maintains cell membrane integrity, also detoxified arsenic from the body. normal skin bacteria mainly composed of gram +ve bacteria. in arsenicosis, this pattern changes from gram +ve bacteria to gram -ve bacteria. still now no study have been conducted to see, the effect of vitamin e on skin bacteria in arsenicosis, as skin bacteria changes. therefore, this study will be conducted to observe any change in aerobic bacterial pattern on the skin of arsenicosis before and after administration of vitamin e capsules. fifteen patients with skin manifestations, 15 arsenic exposed control, 15 healthy volunteers will be recruited on the basis of inclusion and exclusion criteria. they will be provide vitamin e capsules 200 iu twice daily for 12 weeks without any interruption. water and nail samples will be collected for confirming the diagnosis. skin samples will be collected two times (before and after giving vitamin e) for qualitative analysis of bacteria. all the patients, arsenic exposed controls and healthy subjects will be provided with same capsule in same dosage schedule. so, this study will find any change of skin bacteria pattern after administrating vitamin e capsule.

Eligibility criteria:
inclusion criteria (patients): * history of drinking arsenic contaminated water (\>50 µg/l) for more than 6 months * patients having moderate palmar keratosis * patients those voluntarily agree to participate inclusion criteria (arsenic exposed controls): * family members of the patient * history of drinking arsenic contaminated water (\>50 µg/l) * those voluntarily agree to participate * no sign/symptoms of palmar keratosis inclusion criteria (healthy volunteers): * drinking arsenic safe water (\<50 µg/l) * those voluntarily agree to participate exclusion criteria: * pregnant and lactating mother * any other chronic disease like tuberculosis, diabetes, asthma * patients under treatment of arsenicosis
effects of anesthesia with propofol versus desflurane in obese patients

Conditions: Anesthesia; Obesity

Summary: evaluate the effects of propofol compared with desflurane on oxidative stress and inflammation markers in obese patients undergoing scheduled bariatric surgery.

obese patients have a high level of oxidative stress and inflammation activity. desflurane is an anesthetic gas often used for obese patients. propofol, another anesthetic agent, has shown an antioxidant property. the aim of the study is to compare the effects of propofol with desflurane on oxidative stress and inflammation markers in obese patients.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>35 * scheduled gastric by pass surgery * american society of anesthesiologists (asa) \<iii exclusion criteria: * allergic to anesthesia agent * patient refusal

Keywords: oxidative stress bariatric surgery
reducing eskape transmission in the operating room

Conditions: Surgical Procedure, Unspecified

Summary: this study is designed to examine the impact of a personalized, body worn alcohol dispenser on the epidemiology of eskape transmission in the anesthesia work area for patients undergoing surgery requiring general anesthesia.

a solid body of published and preliminary evidence leveraging systematic phenotypic and whole cell genome analysis and innovative surveillance technology has provided great insight into the epidemiology of perioperative bacterial transmission and healthcare-associated infection (hai) development. this work has led us to three primary assertions that serve as the foundation of our scientific premise: 1) further progress towards hai prevention is needed, 2) prevention of perioperative eskape transmission is an important improvement target, and 3) an evidence-based, multi-faceted program can reduce perioperative eskape transmission. further work to generate intraoperative hand hygiene improvement is indicated. we hypothesize that the proposed program will generate sustained reductions in or eskape exposure and s. aureus transmission that will lead to sustained reductions in perioperative hais.

Eligibility criteria:
inclusion criteria: adult patients undergoing surgery requiring general anesthesia and peripheral iv and/or central line placement. exclusion criteria: pediatric patient, not requiring general anesthesia and/or iv/central line placement.
vaginal elasticity assessment before and after surgical repair for urinary stress incontinence.

Conditions: Stress Incontinence, Female

Summary: female patients with usi will be evaluated for vaginal elasticity using vaginal tactile imaging both before and after surgery for the repair of the usi. surgical repair will be performed by a single surgeon who will perform a tension free vaginal tape obturator (tvt-o) repair.

patients will be recruited and sign a consent form. the patients included are patients with usi that are candidates for a tvt-o repair. assessment of vaginal elasticity via vaginal tactile imaging will be performed at 3 different points: * the day of surgery before surgery. * the day after surgery. * 3 months post-operational. every patient will serve as her own control. demographic, gynecologic and obstetric history will be obtained from patients' electronic files.

Eligibility criteria:
inclusion criteria: * any woman undergoing usi repair. exclusion criteria: * women with high grade pelvic floor prolapse.
zd4054 with positron emission tomography/magnetic resonance imaging (pet/mri) for prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this research study is to assess the effects of zd4054 on prostate cancer that has spread to the bones by using new imaging techniques. in particular, this study will use fluorodeoxyglucose (fdg) and 18f-sodium fluoride (naf) pet/computed tomography (ct) and mri scans to look for changes in bone metastasis after zd4054 therapy.


Eligibility criteria:
inclusion criteria: 1. men \> 18 years of age. 2. histologically proven adenocarcinoma of the prostate. 3. presence of radiographic bone metastasis with at least one which is amenable to serial imaging using mri/pet imaging. 4. patients must have evidence of progressive disease by either radiographic progression or a rising psa within 4 weeks prior to registration. 5. patients must have had prior treatment with bilateral orchiectomy or other primary androgen-deprivation therapy. 6. for patients previously treated with flutamide (eulexin), nilutamide (nilandron), or bicalutamide (casodex): patients must have discontinued flutamide \> 4 weeks prior to registration with continued evidence of progressive disease. for bicalutamide or nilutamide, patients must have discontinued the drug \> 6 weeks prior to registration with evidence of progressive disease. 7. prior therapy is permitted as long as it was given \> 4 weeks prior to registration, and evidence for disease progression is met. 8. patients must not have had prior radiotherapy \< 4 weeks prior to registration. 9. prior use of bisphosphonates allowed only if started at least 12 or more weeks prior to registration (can continue current dose/schedule while on study). 10. patient cannot have had prior strontium 89, samarium 153, or other radioisotope. 11. no concurrent use of estrogen, or estrogen-like agents 12. patients must have adequate organ function 13. ecog performance status 0-2. exclusion criteria: 1. use of potent cyp450 inducers (such as phenytoin, rifampicin, carbamazepine and phenobarbitone, st. john's wort) within 2 weeks prior to start of study treatment. 2. prior therapy with endothelin receptor antagonists or family history of hypersensitivity to endothelin antagonists. 3. history of past or current epilepsy, epilepsy syndrome, or other seizure disorder. 4. stage ii, iii or iv cardiac failure (classified according to new york heart association (nyha) classification), myocardial infarction within 6 months prior to study entry, or have left ventricular function (lvef) below the institutional normal limit. 5. qt interval corrected for heart rate (by bazett's correction) (qtcb) \>470 msec. 6. previous history or presence of another cancer, other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years. 7. major surgery within 6 weeks of registration. 8. hemoglobin (hb) \<9 g/dl. concomitant use of erythropoietin or blood transfusions is allowed. 9. inability to take or absorb oral medications.

Keywords: metastatic castrate-resistant prostate cancer bone metastasis
cabergoline in nonfunctioning pituitary adenomas

Conditions: Pituitary Adenoma; Nonfunctioning Pituitary Adenoma

Summary: clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended. we will evaluate the use of cabergoline in a clinical trial, in order to define the efficacy of this treatment in nonfunctioning pituitary adenoma.

nonfunctioning pituitary adenomas (nfpa) are common tumors of sellar region characterized by the absence of clinically hormonal pituitary secretion. these adenomas are typically not diagnosed until they become very large and cause compressive neurologic symptons (e.g. visual impairment or cranial nerve palsy). most of them are able to synthesized gonadotropins but not secreted it. transsphenoidal surgical resection is the first-choice therapy in nfpa. however, complete removal is difficult and tumor rest is very common. in these cases, the pragmatic use of radiotherapy is effective to reduce residual tumor growth or recurrence, but it is related with severe side effects. another possibility is the clinical observation, or wait-to-see approach, but it is associated with tumor progression: 40% in 5-10 years. the efficacy of some medical treatment are not defined yet. since the identification of dopaminergic and somatostatinergic receptors in nfpa, the pharmacological treatment of the nfpa has been considered as a possibility for treatment. to date, clinical use of dopamine agonist (da) in nfpa patients has been evaluated in some studies. however, these studies present modest and inconclusive results and the da role in the npfa management remains undefined. in this study, the investigators plan a clinical trial designed to investigate the efficacy of cabergoline in nfpa individuals with remaining tumor after primary neurosurgery. these results could help to define the efficacy of da in nfpa management.

Eligibility criteria:
inclusion criteria: * presence of pituitary tumor rest at 6 months after neurosurgery * absence of previous hormonal pituitary hypersecretion * absence of previous radiotherapy and/or radiosurgery * histopathological exam showing pituitary adenoma exclusion criteria: * acth immunoexpression at histopathological exam * presence of previous radiotherapy and/or radio surgery * psychotic psychiatric disease * moderate or severe alterations in cardiac valves

Keywords: pituitary adenoma dopaminergic agonist nonfunctioning pituitary adenoma cabergoline
myocardial bridge evaluation towards personalised medicine: the rialto registry

Conditions: Myocardial Bridge

Summary: myocardial bridge (mb) is a congenital anomaly of epicardial circulation characterized by an intramural course of a coronary segment. this anatomical arrangement causes the artery to be squeezed during systole potentially causing flow impairment and ischemia. for this study, mb is defined as the presence of systolic compression in an epicardial vessel causing at least 50% of caliber reduction from diastole. mb can be disabling as it worsens the quality of life. early detection of this congenital condition is crucial, and an invasive functional assessment of the ischemic burden should be considered to evaluate the need for medical or surgical therapy. this is an observational study, involving four italian centres. study objectives are: to assess the risk of future cardiovascular complications in patients with mb referred for coronary angiography and the role of beta-blocker therapy; to describe the clinical and anatomical characteristics of patients presenting with mb; to determine the impact of cardiovascular medications on symptoms in patients with mb; to describe the anatomical and clinical features associated with the invasive evidence of ischemia in patients with mb; to assess the relation between invasively documented ischemia and clinical manifestations in patients with the mb. inclusion criteria: patients referred to undergo ica (for both elective or urgent indications) for suspected coronary artery disease found to have an mb with or without other epicardial lesions amenable to revascularization; age above 18 y.o.; ability to provide informed consent. exclusion criteria are patients with life expectancy below 12 months and patients with severe valvular heart disease. the primary endpoint is the incidence of mace defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization, and target vessel revascularization. the secondary endpoint is evaluating the rate of patients with saq \< 70 and the rate of patients with "high-risk features" on ct scan.


Eligibility criteria:
inclusion criteria: * patients referred to undergo ica (for both elective or urgent indications) for suspected coronary artery disease found to have a myocardial bridge with or without other epicardial lesions amenable to revascularization * age above 18 y.o. * ability to provide informed consent exclusion criteria: * patients with life expectancy below 12 months * patients with severe valvular heart disease

Keywords: myocardial bridge mace ischemia beta-blockers coronary angiography personalised medicine
cryptosporidiosis and enteropathogens in bangladesh

Conditions: Cryptosporidiosis

Summary: the purpose of this study is to explore the role of anti-parasite antibody in protection of children from the parasitic infection cryptosporidiosis. this work has the promise of identifying immune pathways important for protection from parasitic infections of the gut, and will help with designing a vaccine to prevent this infection estimated to cause, from diarrhea and malnutrition, an overall burden of 12 million disability-adjusted life-years in children.


Eligibility criteria:
inclusion criteria: * mother willing to sign informed consent form. * healthy infant * no obvious congenital abnormalities or birth defects. * stable household with no plans to leave the area for the next one year. exclusion criteria: * parents are not willing to have child's blood drawn. * parents are planning to enroll child into another interventional clinical study during the time period of this trial that could affect the outcomes of this study. * mother not willing to have blood drawn and breast milk extracted. * parents not willing to have field research assistant in home two times per week. * history of seizures or other apparent neurologic disorders. * infant has any sibling currently or previously enrolled in this study, including a twin.